Clindamycin HCl Capsule, 300 mg, QTY: 30 Capsules per bottle, Rx Only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701. NDC#: 70518-3772-02
Published May 14, 2025 · Recall initiated: April 22, 2025
Summary
FDA records drug Class II recall D-0411-2025, published May 14, 2025 and initiated April 22, 2025. Recalling firm: RemedyRePack Inc.; Status: Ongoing; Reported quantity: 23 bottles/30 count- 690 capsules; Lot: Lot#: B3698036-033125, B3688703-032625, Exp.: 07/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- RemedyRePack Inc.
- Distributor
- Within U.S - PA, VA, FL.
- Lot
- Lot#: B3698036-033125, B3688703-032625, Exp.: 07/31/2026.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAtemper tamer, 1 US fl oz. (29.6 mL), Homeopathic Oral Spray, Manufactured by: Siddha Flower Essences, Oxnard,May 14, 2025
- FDATESTOSTERONE PELLET 100 mg (with Cholesterol </=4%), 1 Pellet for Subcutaneous Use, This is a Compounded Drug,May 14, 2025
- FDAFentaNYL 500mcg (2mcg/mL) and Ropivacaine HCl 250mg (0.1%) added to 250 mL, 0.9% Sodium Chloride InjectionMay 14, 2025
- FDATESTOSTERONE PELLET 200 mg (with Cholesterol </=2%), 1 Pellet for Subcutaneous Use, This is a Compounded Drug,May 14, 2025
- FDAPolyvinyl Alcohol Ophthalmic Solution 1.4%, Lubricant Eye Drops, Moisturizing, Sterile, 0.5 FL OZ (15mL) perMay 14, 2025
- FDATESTOSTERONE PELLET 200 mg BLUNT (with Cholesterol </=2%), 1 Pellet for Subcutaneous Use, This is a CompoundedMay 14, 2025
Questions about this recall
Was Clindamycin HCl Capsule, 300 mg, QTY: 30 Capsules per bottle, Rx Only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701. NDC#: 70518-3772-02 recalled?
Yes. FDA published recall D-0411-2025 on May 14, 2025. Reported hazard: CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail